Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL) (CONTROL)
A Phase 2, Randomized, Double Blind, Placebo Controlled Clinical Study Investigating the Effects of Obeticholic Acid and Atorvastatin Treatment on Lipoprotein Metabolism in Subjects With Nonalcoholic Steatohepatitis
Sponsor: Intercept Pharmaceuticals
A PHASE2 clinical study on Nonalcoholic Steatohepatitis, this trial is completed. The trial is conducted by Intercept Pharmaceuticals and has accumulated 11 data snapshots since 2015. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
-
Jul 2018 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Dec 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Intercept Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .